mprop="name">Eric Clarke . Clarke brings over 17 years of extensive health care and financial expertise. Prior to joining Pharmagen, Clarke served as part of the leadership team at MedStar Health; a $4 billion diversified health system in the Washington D.C.
region, which includes leading medical facilities such as Washington Hospital Center and Georgetown University Hospital. Additionally, Clarke formally served as the Managing Director in charge of the Washington D.C.
, Risk Management Practice for a national professional services firm, providing expert advice and service in forensic accounting, SEC reporting, and Sarbanes-Oxley Compliance.
With an eye on profitability, the company continues to keep operating expenses as low as possible and is actively exploring all opportunities that benefit shareholders. These endeavors include but are not limited to a strategic relocation to lower the company's tax burden, growing the company's institutional shareholder base by partnering with investment banks and a professional investment relations firm, attending financial conferences and staying at the forefront of health policy by engaging health regulators.
Leveraging our understanding of drug shortages, our long term goal is to become an FDA approved manufacturer of habitually short supply, sterile pharmaceuticals. Through an industry changing, cGMP + ® process, employing single-use, modular systems, we intend to be the gold standard of sterile production in the United States.
Pharmagen, Inc. ("Pharmagen"), and wholly owned subsidiaries and operating divisions Pharmagen Laboratories, Inc., Pharmagen Distribution, LLC and Pharmagen Nutraceuticals, Inc. is the leader in innovative solutions to the nations sterile pharmaceutical crisis. With a multifaceted approach, Pharmagen is meeting the demand of health provider market through dynamic, inPage: 1 2 3 Related medicine technology :1
. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes2
. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 20123
. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies4
. Misonix Announces New Distribution Agreement For Panama5
. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park6
. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center7
. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter8
. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability9
. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors10
. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study11
. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast